Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Kymera Therapeutics (KYMR) Net Margin (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Net Margin for 7 consecutive years, with 3030.7% as the latest value for Q4 2025.

  • Quarterly Net Margin fell 207381.0% to 3030.7% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 794.06% through Dec 2025, down 31850.0% year-over-year, with the annual reading at 794.04% for FY2025, 31847.0% down from the prior year.
  • Net Margin for Q4 2025 was 3030.7% at Kymera Therapeutics, down from 2973.05% in the prior quarter.
  • The five-year high for Net Margin was 30.01% in Q4 2023, with the low at 3030.7% in Q4 2025.
  • Average Net Margin over 5 years is 700.7%, with a median of 366.95% recorded in 2022.
  • The sharpest move saw Net Margin surged 51299bps in 2021, then plummeted -207381bps in 2025.
  • Over 5 years, Net Margin stood at 222.88% in 2021, then rose by 3bps to 216.03% in 2022, then soared by 86bps to 30.01% in 2023, then tumbled by -3089bps to 956.88% in 2024, then tumbled by -217bps to 3030.7% in 2025.
  • According to Business Quant data, Net Margin over the past three periods came in at 3030.7%, 2973.05%, and 667.6% for Q4 2025, Q3 2025, and Q2 2025 respectively.